These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19309249)

  • 1. Safety of 17D derived yellow fever vaccines.
    Domingo C; Niedrig M
    Expert Opin Drug Saf; 2009 Mar; 8(2):211-21. PubMed ID: 19309249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Yellow fever].
    Wiercińska-Drapało A
    Przegl Epidemiol; 2004; 58 Suppl 1():101-5. PubMed ID: 15807166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
    Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
    Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.
    Kitchener S
    Vaccine; 2004 Jun; 22(17-18):2103-5. PubMed ID: 15149765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
    van de Pol EM; Gisolf EH; Richter C
    J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viscerotropic disease following yellow fever vaccination in Peru.
    Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
    Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rarity of adverse effects after 17D yellow-fever vaccination.
    Marianneau P; Georges-Courbot M; Deubel V
    Lancet; 2001 Jul; 358(9276):84-5. PubMed ID: 11463403
    [No Abstract]   [Full Text] [Related]  

  • 10. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
    Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
    J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How many published cases of serious adverse events after yellow fever vaccination meet Brighton Collaboration diagnostic criteria?
    Thomas RE; Spragins W; Lorenzetti DL
    Vaccine; 2013 Dec; 31(52):6201-9. PubMed ID: 24436960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
    Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
    J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.
    Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
    Am J Trop Med Hyg; 2012 Feb; 86(2):359-72. PubMed ID: 22302874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute viscerotropic disease following vaccination against yellow fever.
    Hayes EB
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
    Julander JG; Testori M; Cheminay C; Volkmann A
    Front Immunol; 2018; 9():1756. PubMed ID: 30116244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
    Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
    J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.
    Vasconcelos PF; Luna EJ; Galler R; Silva LJ; Coimbra TL; Barros VL; Monath TP; Rodigues SG; Laval C; Costa ZG; Vilela MF; Santos CL; Papaiordanou PM; Alves VA; Andrade LD; Sato HK; Rosa ES; Froguas GB; Lacava E; Almeida LM; Cruz AC; Rocco IM; Santos RT; Oliva OF;
    Lancet; 2001 Jul; 358(9276):91-7. PubMed ID: 11463409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?
    Barrett AD; Teuwen DE
    Curr Opin Immunol; 2009 Jun; 21(3):308-13. PubMed ID: 19520559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.